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In cooperation with the Community 
Colleges of Iowa, the Immunization 
Program will be conducting regional 
immunization training this spring.  
On alternating years the 
Immunization Program conducts 
Regional Trainings opposite a 
statewide conference.  Trainings for 
2006 have been scheduled for April 
20 through May 25 at a variety of 
locations throughout the state.  The 
trainings will include information 
regarding the 2006 immunization 
schedule, new vaccines, Vaccines for 
Children Program guidelines, vaccine 
storage and handling requirements, 
and recent changes to Iowa 
Administrative Code 641, Chapter 7.   
 
The training brochure, including 
training dates and locations is 
available on the Iowa Department of 
Public Health website at 
www.idph.state.ia.us/conferences.asp.   
 
Trainings will be held at the 
following dates and sites:  
 
April 20,  Cherokee, 12:00-4:00 
To register call 1-800-352-4649 
 
April 24,  Cedar Rapids, 12:00-4:00 
To register call 1-800-332-8833 
 
April 27,  Creston, 9:00-1:00 
To register call 1-800-247-4023 ext. 
441 or ext. 449 
 
May 17, Ottumwa, 12:00-4:00 
To register call 1-800-726-2585 ext. 
5281 
 
May 23,  Ankeny, 9:00-1:00 
To register call 1-800-342-0033 
 
May 25, Mason City,  8:30-12:30  
To register call 1-888-466-4222 ext. 
4358 
Pediarix– When Can I give it?  
2006 Regional Trainings  
Pediarix (Diphtheria, Tetanus, 
acellular Pertussis [DTaP], Hepatitis 
B and IPV) vaccine is licensed for the 
primary series for children 6 weeks 
through 6 years of age.  A “primary 
series” is the first three doses of a 
series (example: an infant beginning 
the series at 2 months or a 3 year old 
that has not received immunizations 
and is starting the series). Spacing of 
any combination vaccine including 
Pediarix is determined by the 
antigens in the vaccine.  The first, 
second and third dose of DTaP and 
IPV can be given one month apart. 
The minimum interval for Hepatitis 
B is one month between the first and 
second dose, 
 2 months between the second and 
third dose.  In addition, the third 
dose must be 4 months from the first 
with a minimum age of 6 months.  
Minimum intervals for the 
administration of Pediarix is dictated 
by the minimum spacing intervals for 
Hepatitis B vaccine.  If you have 
questions regarding specific scenarios 
please contact the Immunization 
Program at 1-800-831-6293.  
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Dose Minimum Age Minimum Interval  
    from Previous Dose 
 1  6 weeks  NA 
 2  10 weeks  4 weeks 
 3  6 months  8 weeks 
Pediarix Minimum Interval Chart 
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Iowa’s  
Immunization  
Registry Information  
System (IRIS)  
 
Enroll Today! 
 
Call the IRIS  
Help Desk at 
 1-800-374-3958  
for Enrollment Details 
or IRIS Questions. 
 
This newsletter is a 
quarterly publication and 
contains important updates 
and immunization 
information.  Please share 
this newsletter with your 
coworkers.   
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Help Us Help You! 
Is this newsletter helpful to 
you?  What articles would you 
like to see?  Please contact 
Bridget Konz at 
bkonz@idph.state.ia.us or  
1-800-831-6293 ext. 7. 
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In January 2006, the Advisory 
Committee on Immunization 
Practices (ACIP) released a new 
Harmonized Childhood and 
Adolescent Immunization 
Schedule for 2006. To view the 
complete MMWR article, please 
visit: http://www.cdc.gov/mmwr/
preview/mmwrhtml/mm5451-
Immunizationa1.htm.  The 
following is a brief overview of the 
changes to the 2006 schedule and 
catch-up schedule.  
 
Hepatitis B  
Vaccination of infants born to 
hepatitis B surface antigen 
(HBsAg)-negative mothers can be 
delayed in rare circumstances, but 
only if a physician's order to 
withhold the vaccine and a copy of 
the mother's original HBsAg-
negative laboratory report are 
documented in the infant's 
medical record. Every effort 
should be made to only provide 
three doses of hepatitis B to 
infants but it is permissible to 
administer four doses (e.g., when 
combination vaccines are 
administered after the birth dose).  
For infants born to HBsAg-
positive mothers, testing for 
HBsAg and antibody to HBsAg 
after completion of the vaccine 
series should be conducted at age 
9 - 18 months, or 3 - 9 months 
from the final dose of vaccine 
(generally at the next well-child 
visit after completion of the 
vaccine series).  The December 23, 
2005 issue of the MMWR that 
speaks directly to Hepatitis B can 
be found at: 
http://www.cdc.gov/mmwr/preview
/mmwrhtml/rr5416a1.htm  
Tdap 
A new tetanus toxoid, reduced 
diphtheria toxoid, and acellular 
pertussis vaccine (Tdap) is 
recommended for adolescents 
aged 11 - 12 years who have 
completed the recommended 
childhood DTP/DTaP vaccination 
series and have not received a 
tetanus and diphtheria toxoid (Td) 
booster dose. Adolescents aged 13 
- 18 years who missed the age 11 - 
12-year Td/Tdap booster dose 
should also receive a single dose of 
Tdap if they have completed the 
recommended childhood 
DTP/DTaP vaccination series. 
Subsequent Td boosters are 
recommended every 10 years. 
 
The catch-up schedule for persons 
aged 7 - 18 years has been 
changed for Td; Tdap may be 
substituted for any dose in a 
primary catch-up series or as a 
booster if age appropriate for 
Tdap.  A 5-year interval from the 
last Td dose is encouraged when 
Tdap is used as a booster dose. 
 
Meningococcal  
Meningococcal conjugate vaccine 
(MCV4) should be administered to 
all children at age 11 - 12 years as 
well as to unvaccinated 
adolescents at high school entry 
(age 15 years). All college 
freshmen living in dormitories 
should also be vaccinated with 
MCV4 or meningococcal 
polysaccharide vaccine (MPSV4). 
For prevention of invasive 
meningococcal disease, 
vaccination with MPSV4 for 
children aged 2 - 10 years and 
with MCV4 for older children in 
certain high-risk groups is 
recommended.  
 
Influenza 
The schedule recommends 
influenza vaccine for children 
aged > 6 months with certain risk 
factors, healthcare workers, and 
others with close contact with 
persons in high risk groups.  In 
addition, healthy children 6-23 
months of age and close contacts 
of children 0-5 months are 
recommended to receive influenza 
vaccine.  During the February, 
ACIP meeting the committee 
voted to expand the 
recommendation for routine 
influenza vaccination to include 
all children 2-5 years of age, as 
well as household contacts and 
out-of-home caregivers of these 
children. 
 
Hepatitis A  
Hepatitis A vaccine is now 
universally recommended for all 
children at 1 year of age (12- 23 
months). Hepatitis A is a 2 doses 
series with a 6 month minimum 
interval between doses.  
2006 - ACIP Immunization Schedule  
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Iowa Immunization Program  
1-800-831-6293 
Useful Websites for  
Immunization Providers 
 
Centers for Disease Control and 
Prevention / National  
Immunization Program 
www.cdc.gov/nip   
 
The Immunization Action Coalition 
www.immunize.org 
 
Children’s Hospital of Philadelphia  
www.vaccine.chop.edu  
 
American Academy of Pediatrics 
www.aap.org 
 
Iowa Immunization Program 
www.idph.state.ia.us/adper/
immunization.asp 
News You Can Use  
Hepatitis A vaccine has now been 
incorporated into the “Recommended 
Childhood and Adolescent 
Immunization Schedule” published 
by the Advisory Committee on 
Immunization Practices in January, 
2006.  Hepatitis A vaccine is 
recommended for all children 12 
through 23 months of age.   
 
There are two manufacturers of 
Hepatitis A vaccine: Havrix 
(GlaxoSmithKline) and VAQTA 
(Merck & Co.).  Both companies offer 
pediatric (12 months through 18 
years) and adult (19 years of age and 
older) vaccine.   
 
The final version of the Hepatitis A 
vaccine information statement has 
been approved and is dated 3/21/06.  
  
The Iowa VFC Program anticipates 
providing hepatitis A vaccine to VFC-
eligible children who are 1 year of 
age beginning the summer of 2006. 
Additional information will be sent to 
VFC Providers regarding the 
implementation date and covered age 
cohorts.   
Iowa Code Chapter 135.39(B), 
Early Childhood Immunizations  
was effective January 1, 2006.  
This chapter stipulates that early 
childhood immunizations (those 
administered to children less than 
eight years of age) administered 
in Iowa shall not contain more 
than trace amounts of mercury.  
This section does not apply to 
early childhood immunizations for 
influenza or in times of emergency 
or epidemic as determined by the 
director of public health.  The 
following link provides 
information from the U.S. Food 
and Drug Administration 
regarding thimerosal (the 
mercury containing preservative) 
in vaccines: www.fda.gov/cber/
vaccine/thimerosal.htm.  
    
Since mid-2001, vaccines 
routinely recommended for 
infants in the United States have 
been manufactured either without 
or with only trace amounts of 
thimerosal.  A preservative-free 
version of the inactivated 
influenza vaccine (contains trace 
amounts of thimerosal) is 
available in limited supply at this 
time for use in infants, children 
and pregnant women.  Some 
vaccines such as Td, which is 
indicated for older children (> 7 
years of age) and adults, are also 
now available in formulations 
that are free of thimerosal or 
contain only trace amounts.  
Vaccines with trace amounts of 
thimerosal contain 1 microgram 
or less of mercury per dose. 
 
Communicating with parents and 
vaccine recipients regarding this 
issue have become complex.  
Below are some websites to assist 
you in providing accurate 
information to families.   
 
Information regarding mercury and 
vaccines  http://www.cdc.gov/nip/
vacsafe/concerns/thimerosal/
default.htm#facts 
 
Immunization information for 
parents  http://
www.immunizationinfo.org/parents/
index.cfm 
 
Vaccine misinformation  http://
www.immunizationinfo.org/
immunization_issues_detail.cfv?id=52 
 
Evaluating information about 
vaccines on the internet  http://
www.immunizationinfo.org/
immunization_issues_detail.cfv?id=102 
efficacy as single antigen 
varicella vaccine. 
  
One dose of MMRV vaccine 
should be administered on or 
after the first birthday, 
preferably as soon as the child 
becomes eligible for vaccination.  
MMRV is indicated for 
immunization of persons 12 
months though 12 years of age. 
MMRV vaccine may be used 
whenever any components of the 
combination vaccine are 
indicated and the other 
components are not 
ProQuad, measles, mumps, 
rubella and varicella (MMRV) 
vaccine is manufactured by 
Merck.  ProQuad was licensed by 
the Food and Drug 
Administration on September 6, 
2005.  The attenuated MMR 
vaccine viruses in ProQuad are 
identical and of equal titer to 
those in the MMR vaccine.  The 
titer of Varicella-Zoster virus is 
higher in MMRV than in single 
antigen Varicella vaccine.  The 
increased varicela titer in the 
combination vaccine was 
necessary to maintain the same 
contraindicated.  Using 
combination vaccines containing 
some antigens not indicated at 
the time of administration may 
be justified.  Receiving additional 
doses of vaccine beyond the 
recommended amount may be 
justified when products that 
contain only the needed antigens 
are not readily available or would 
result in extra injections, and 
potential benefits to the child 
outweigh the risk of adverse 
events associated with the extra 
antigen(s). 
 
ProQuad – Dosage & Recommendations 
Measles, Mumps, Rubella, & Varicella Vaccine 
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Hepatitis A Recs Iowa Thimerosal Law 
2006 Changes to Iowa’s Immunization Law 
Administrative Code Chapter 641.7 
with at least 1 dose of diphtheria/
tetanus/pertussis-containing 
vaccine received after the 
applicant’s fourth birthday if the 
applicant was born after 
September 15, 2000.  This change 
will require most children 
entering kindergarten in the fall 
of 2006, to have four doses of 
DTaP vaccine.   
 
The current version of Chapter 7 
is available on the Immunization 
Program web page at 
www.idph.state.ia.us/adper/
common/pdf/immunization/
iowas_imm_code_ch7_641.pdf.  If 
you have any questions regarding 
this change, please contact 
Marnell Kretschmer at  
1-800-831-6293 ext 3. 
As a result, the Immunization 
Program presented the corrected 
language to the Board of Health 
on January 11, 2006, and 
requested an emergency filing.  
The changes were accepted by 
the board and went into effect 
January 11, 2006 and were 
published on February 1, 2006.  
Updated copies of Chapter 7 were 
sent to all VFC Program 
Providers and school nurses.  
 
The corrected language for 
children attending elementary 
school is as follows:  four years of 
age and older, 3 doses, with at 
least 1 dose of diphtheria/
tetanus/pertussis-containing 
vaccine received after the 
applicant’s fourth birthday if the 
applicant was born on or before 
September 15, 2000; or 4 doses, 
During 2005, the Immunization 
Program in conjunction with the 
Immunization Advisory Group 
made numerous changes to 
Chapter 7:  Immunization and 
Immunization Education: 
Persons Attending Elementary or 
Secondary Schools, Licensed 
Child Care Centers or 
Institutions of Higher Education.   
An error was identified in the 
most recent changes; an incorrect 
date for the DTaP vaccine 
requirement for children 
attending elementary school was 
reported.  Due to the age 
requirements to attend school, 
only individuals born on 
September 15, 2001 would have 
been required to have four doses 
of DTaP for the 2006-07 school 
year.   
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ACIP Meeting 
February Update 
The Advisory Committee on 
Immunization Practices (ACIP) 
met in Atlanta, February 21-
22.   During the meeting, ACIP 
voted to recommend the new 
rotavirus vaccine, RotaTeq, for all 
infants. RotaTeq is a three-dose, 
oral vaccine routinely  
administered at two, four and six 
months of age.  The vaccine is 
74% effective against any 
rotavirus disease, and 98% 
effective in preventing severe 
disease.  
 
ACIP also voted to expand the 
recommendation for routine 
influenza vaccination to include 
all children 2-5 years of age, as 
well as household contacts and 
out-of-home caregivers of these 
children.  In addition, the 
committee voted to expand VFC 
influenza vaccine coverage for all 
eligible children 6 months through 
18 years.  The Committee 
recommended that tiering of 
influenza vaccine not be 
implemented during years with 
sufficient vaccine supply. 
 
During the meeting the Committee 
heard several presentations on 
Tdap vaccine, which was 
recommended in 2005 for routine 
administration to adolescents 11-18 
years of age.  ACIP strengthened 
their recommendations for use of 
Tdap among certain health care 
workers (HCWs), by recommending 
that all HCWs who work in 
hospitals and ambulatory care 
settings and have direct patient 
contact receive the vaccine as soon 
as feasible, at an interval as short 
as two years from their last dose of 
Td.  Those HCWs who do not have 
direct patient contact should 
continue to receive one dose of the 
vaccine as a replacement for Td, in 
accordance with the committee’s 
recommendation for general Tdap 
use among adults.  The 
Committee also discussed 
recommending the vaccine for 
adults over the age of 65, but 
chose not to do so at this time.   
 
Presentations from the ACIP 
meetings are available online at  
http://www.cdc.gov/nip/ACIP/mtg-
slides-feb06.htm.  The next ACIP 
meeting will be held June 29-30 , 
2006.   
Chickenpox  12/16/98 
DTaP  7/30/01 
Hib  12/16/98 
Hepatitis A  3/21/06 
Hepatitis B  7/11/01  
Influenza  
 Intranasal 10/20/05 
 Inactivated 10/20/05   
MMR 1/15/03 
Meningococcal  10/07/05 (Interim) 
Pneumococcal 
 Poly. (PPV23) 7/29/97 
 Conj. (PCV7) 9/30/02 
Polio (IPV)  1/01/00  
Td  6/10/94 
Tdap 9/22/05 (Interim) 
Current Vaccine Information  
Statement (VIS) Dates 
